zidesamtinib
Generic: Zidesamtinib
zidesamtinib: 2 clinical trials tracked.
zidesamtinib evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about zidesamtinib, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (2)
Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
Expanded Access30 sites · Australia, Belgium, Canada, France…Nuvalent Inc.
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
Primary endpoint: Maximum Tolerated Dose (MTD) (Phase 1)
Interventionalopen359 targetStarted 2022-01Completion 2028-1250 sites · Australia, Belgium, Canada, France…Nuvalent Inc.